scholarly journals Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

2020 ◽  
Vol 10 (1) ◽  
pp. 32
Author(s):  
Ileana Andreea Ratiu ◽  
Tomasz Ligor ◽  
Victor Bocos-Bintintan ◽  
Chris A Mayhew ◽  
Bogusław Buszewski

Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of death worldwide by cancer is that of the lung, which, in large part, is a result of the disease often not being detected until a late stage. Although COPD and asthma are conditions with considerably lower mortality, they are extremely distressful to people and involve high healthcare overheads. Moreover, for these diseases, diagnostic methods are not only costly but are also invasive, thereby adding to people’s stress. It has been appreciated for many decades that the analysis of trace volatile organic compounds (VOCs) in exhaled breath could potentially provide cheaper, rapid, and non-invasive screening procedures to diagnose and monitor the above diseases of the lung. However, after decades of research associated with breath biomarker discovery, no breath VOC tests are clinically available. Reasons for this include the little consensus as to which breath volatiles (or pattern of volatiles) can be used to discriminate people with lung diseases, and our limited understanding of the biological origin of the identified VOCs. Lung disease diagnosis using breath VOCs is challenging. Nevertheless, the numerous studies of breath volatiles and lung disease provide guidance as to what volatiles need further investigation for use in differential diagnosis, highlight the urgent need for non-invasive clinical breath tests, illustrate the way forward for future studies, and provide significant guidance to achieve the goal of developing non-invasive diagnostic tests for lung disease. This review provides an overview of these issues from evaluating key studies that have been undertaken in the years 2010–2019, in order to present objective and comprehensive updated information that presents the progress that has been made in this field. The potential of this approach is highlighted, while strengths, weaknesses, opportunities, and threats are discussed. This review will be of interest to chemists, biologists, medical doctors and researchers involved in the development of analytical instruments for breath diagnosis.

Metabolites ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 317
Author(s):  
Michalis Koureas ◽  
Paraskevi Kirgou ◽  
Grigoris Amoutzias ◽  
Christos Hadjichristodoulou ◽  
Konstantinos Gourgoulianis ◽  
...  

The aim of the present study was to investigate the ability of breath analysis to distinguish lung cancer (LC) patients from patients with other respiratory diseases and healthy people. The population sample consisted of 51 patients with confirmed LC, 38 patients with pathological computed tomography (CT) findings not diagnosed with LC, and 53 healthy controls. The concentrations of 19 volatile organic compounds (VOCs) were quantified in the exhaled breath of study participants by solid phase microextraction (SPME) of the VOCs and subsequent gas chromatography-mass spectrometry (GC-MS) analysis. Kruskal–Wallis and Mann–Whitney tests were used to identify significant differences between subgroups. Machine learning methods were used to determine the discriminant power of the method. Several compounds were found to differ significantly between LC patients and healthy controls. Strong associations were identified for 2-propanol, 1-propanol, toluene, ethylbenzene, and styrene (p-values < 0.001–0.006). These associations remained significant when ambient air concentrations were subtracted from breath concentrations. VOC levels were found to be affected by ambient air concentrations and a few by smoking status. The random forest machine learning algorithm achieved a correct classification of patients of 88.5% (area under the curve—AUC 0.94). However, none of the methods used achieved adequate discrimination between LC patients and patients with abnormal computed tomography (CT) findings. Biomarker sets, consisting mainly of the exogenous monoaromatic compounds and 1- and 2- propanol, adequately discriminated LC patients from healthy controls. The breath concentrations of these compounds may reflect the alterations in patient’s physiological and biochemical status and perhaps can be used as probes for the investigation of these statuses or normalization of patient-related factors in breath analysis.


2012 ◽  
Vol 11 (4) ◽  
pp. 129-137 ◽  
Author(s):  
Yishan Wang ◽  
Yanjie Hu ◽  
Di Wang ◽  
Kai Yu ◽  
Ling Wang ◽  
...  

2021 ◽  
Author(s):  
Imadeddine Azzouz ◽  
Mohammad Sharif Khan ◽  
Andrew C. Bishop ◽  
Khaldoun Bachari

This chapter introduces the significance of exploring volatile organic compounds (VOC) in clinical samples. Because exhaled-breath is easy to collect, unlimited, and instruments are already commercially available, VOC analysis in exhaled breath seems to be a promising tool for non-invasive detection of many diseases including infections, respiratory diseases, and cancers. Here, we have focused on some appropriate technologies to extract, pre-concentrate, and evaluate VOC biomarkers in exhaled breath. The second part of this chapter discusses the comprehensive GC × GC in bio-VOCs analysis and illustrates the potential of using this analytical technique.


Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2317
Author(s):  
Dima Augustin Catalin ◽  
Balaban Daniel Vasile ◽  
Dima Alina

Volatile organic compounds (VOCs) are part of the exhaled breath that were proposed as non-invasive breath biomarkers via different human discharge products like saliva, breath, urine, blood, or tissues. Particularly, due to the non-invasive approach, VOCs were considered as potential biomarkers for non-invasive early cancer detection. We herein aimed to review the data over VOCs utility in digestive neoplasia as early diagnosis or monitoring biomarkers. A systematic literature search was done using MEDLINE via PubMed, Cochrane Library, and Thomson Reuters’ Web of Science Core Collection. We identified sixteen articles that were included in the final analysis. Based on the current knowledge, we cannot identify a single VOC as a specific non-invasive biomarker for digestive neoplasia. Several combinations of up to twelve VOCs seem promising for accurately detecting some neoplasia types. A combination of different VOCs breath expression are promising tools for digestive neoplasia screening.


2022 ◽  
Author(s):  
Dapeng Chen ◽  
Noella A. Bryden ◽  
Wayne A. Bryden ◽  
Michael McLoughlin ◽  
Dexter Smith ◽  
...  

Abstract Human breath contains trace amounts of non-volatile organic compounds (NOCs) which might inform non-invasive methods for evaluation of individual health. In previous work, we demonstrated that lipids detected in exhaled breath aerosol (EBA) could be used as markers of active tuberculosis (TB). Here, we advanced our analytical platform in characterizing small metabolites and lipids in EBA samples collected from participants enrolled in clinical trials designed to identify molecular signatures of active TB. EBA samples from 26 participants with active TB and 73 healthy participants were processed using a dual-phase extraction method, and metabolites and lipids were identified via mass spectrometry (MS) database matching. In total, 13 metabolite and 9 lipid markers were identified with optimized relative standard deviation values that were statistically different between individuals diagnosed with active TB and the healthy controls. A feature ranking algorithm reduced this number to 10 molecules, with the membrane glycerophospholipid, phosphatidylinositol 24:4, emerging as top driver of segregation between the two groups. These results support the utility of this approach to identify consistent NOC signatures from EBA samples in active TB cases and suggest the potential to apply this method to other human diseases which alter respiratory NOC release.


Sign in / Sign up

Export Citation Format

Share Document